Study wrapper · #823
Real-World Effectiveness and 12-Month Persistence of a Semaglutide-Supported Digital Weight-Loss Service: A Retrospective Cohort Study in Germany.
Editor's note
A real-world retrospective cohort (4,535 patients) of a semaglutide-supported commercial digital weight-loss service in Germany. Semaglutide is genuinely the pharmacological anchor, but the study's real subject is adherence and persistence, not the drug's efficacy per se — and its most instructive finding is the gap between conditions. Among the 12% who stayed fully adherent, mean weight loss was 15.13%; but the whole-cohort figure was 9.47% by last-observation-carried-forward and just 2.40% under a worst-case model assuming zero loss for the 88% who dropped out. That spread is the story: real-world effectiveness is heavily conditional on persistence, and attrition was severe in this unsubsidised setting. Notable predictors included higher churn among patients with three or more comorbidities and, interestingly, among prior GLP-1 users. Caveats: retrospective, single commercial program, no control arm, and outcomes shaped by service design as much as by semaglutide. Useful for the real-world-adherence angle, weighted accordingly.
Plain-language abstract
This study looked at how well people actually did on a commercial online weight-loss program in Germany that used semaglutide, tracking 4,535 people over a year. The key lesson is how much results depended on sticking with the program. Among the roughly 12% of people who stayed fully engaged — taking the medication and logging their data — average weight loss was about 15%. But looking at everyone who started, average weight loss was about 9.5% by one accounting method, and only about 2.4% under a stricter method that assumed the many people who dropped out lost no weight at all. Nearly 88% did not stay with the program, which was not subsidised. The researchers found that people with three or more other health conditions were more than twice as likely to drop out, and, surprisingly, people who had used a GLP-1 drug before were also more likely to quit. Because this looked back at records from a single commercial program with no comparison group, the results reflect the program's design and its participants as much as the drug itself, and show that real-world success hinges heavily on staying the course.